New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - dornase alfa 1 mg/ml;   - solution for inhalation - 2.5mg/2.5ml - active: dornase alfa 1 mg/ml   excipient: calcium chloride dihydrate sodium chloride water for injection - management of cystic fibrosis (cf) patients with a forced vital capacity (fvc) of greater than 40% of predicted to improve pulmonary function.

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - vismodegib 150mg;   - capsule - 150 mg - active: vismodegib 150mg   excipient: gelatin iron oxide black iron oxide red lactose monohydrate magnesium stearate microcrystalline cellulose opacode black s-1-17822 opacode black s-1-17823 povidone purified talc sodium laurilsulfate sodium starch glycolate titanium dioxide - indicated for the treatment of adult patients with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma where surgery and/or radiation therapy are not appropriate.

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - rituximab 120 mg/ml;   - solution for injection - 1400mg/11.7ml - active: rituximab 120 mg/ml   excipient: histidine histidine hydrochloride hyaluronidase methionine polysorbate 80 trehalose dihydrate water for injection - non-hodgkin's lymphoma mabthera is indicated for the treatment of patients with: · cd20 positive, previously untreated low-grade or follicular, b-cell non-hodgkin's lymphoma in combination with chemotherapy, · cd20 positive, relapsed or chemoresistant low-grade or follicular, b-cell non-hodgkin's lymphoma, · cd20 positive diffuse large b-cell non-hodgkin's lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy. mabthera is indicated for maintenance treatment of patients with cd20 positive, low grade or follicular, b-cell non-hodgkin's lymphoma.

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - rituximab 1600mg;   - solution for injection - 1600mg/13.4ml - active: rituximab 1600mg   excipient: histidine histidine hydrochloride methionine polysorbate 80 trehalose dihydrate vorhyaluronidase alfa water for injection - mabthera sc 1600 mg in combination with chemotherapy is indicated for the treatment of patients with chronic lymphocytic leukaemia

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - fluorouracil 31.25 mg/ml - oral solution - 250 mg/8ml - active: fluorouracil 31.25 mg/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - fluorouracil 25 mg/ml - solution for injection - 250 mg/10ml - active: fluorouracil 25 mg/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - pirfenidone 267mg;   - capsule - 267 mg - active: pirfenidone 267mg   excipient: croscarmellose sodium gelatin magnesium stearate microcrystalline cellulose opacode brown s-1-16530 povidone purified water titanium dioxide - esbriet is indicated for the treatment of idiopathic pulmonary fibrosis (ipf)

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - pirfenidone 267mg - film coated tablet - 267 mg - active: pirfenidone 267mg excipient: colloidal silicon dioxide croscarmellose sodium iron oxide yellow macrogol 3350 magnesium stearate microcrystalline cellulose polyvinyl alcohol povidone purified talc titanium dioxide - indicated for the treatment of idiopathic pulmonary fibrosis (ipf).

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - pirfenidone 534mg - film coated tablet - 534 mg - active: pirfenidone 534mg excipient: colloidal silicon dioxide croscarmellose sodium iron oxide red iron oxide yellow macrogol 3350 magnesium stearate microcrystalline cellulose polyvinyl alcohol povidone purified talc titanium dioxide - indicated for the treatment of idiopathic pulmonary fibrosis (ipf).

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - pirfenidone 801mg - film coated tablet - 801 mg - active: pirfenidone 801mg excipient: colloidal silicon dioxide croscarmellose sodium iron oxide black iron oxide red macrogol 3350 magnesium stearate microcrystalline cellulose polyvinyl alcohol povidone purified talc titanium dioxide - indicated for the treatment of idiopathic pulmonary fibrosis (ipf).